Hemophagocytic Lymphohistiocytosis Secondary to Bone Marrow Only B-Cell Lymphoma: A Very Rare Entity With an Even Rarer Presentation

Ami Patela, d, Anusha Vakitib, Abhishek Chilkulwar, Prerna Mewawalla

Abstract

Hemophagocytic lymphohistiocytosis (HLH) is a rare hyperinflammatory syndrome. It is categorized as familial or acquired, most commonly caused by infections, malignancies, rheumatologic and immunodeficiency disorders. Irrespective of the etiology, the age at the onset is the strongest prognostic factor, hence it is extremely important to have a high suspicion for HLH, diagnose it promptly and initiate treatment without any delay. We encountered a 70-year-old female patient who initially presented with left-sided facial weakness and pancytopenia, secondary to diffuse stage IV B diffuse large B-cell lymphoma with isolated bone marrow involvement with secondary HLH.

Keywords: HLH; Primary bone marrow diffuse large B-cell lymphoma

Introduction

The secondary involvement of malignant lymphomas in the bone marrow is common, whereas primary bone marrow diffuse large B-cell lymphoma (DLBCL) constitutes a rare but distinctive hematological process with a poor prognosis. Hemophagocytic lymphohistiocytosis (HLH) has a well-known association with lymphomas. However, being a unique hyperinflammatory syndrome, it is a diagnostic challenge, primarily due to lack of familiarity amongst physicians. HLH manifesting as a clinical consequence of primary bone marrow lymphoma (PBML) is a rare entity. This is the first case of HLH reported in association with bone marrow only B-cell lymphoma.

Here we present a case of PBML with secondary HLH in which prompt diagnosis and treatment with combination chemotherapy achieved early remission of the lymphoma and HLH.

Such clinical scenarios broaden our diagnostic horizon and emphasize that early recognition is critical to institution of timely therapy to prevent devastating consequences.

Case Report

A 70-year-old female with recent diagnosis of Bell’s palsy 2 weeks prior to admission on treatment with valcyclovir presented to the hospital with worsening left facial weakness, fatigue, night sweats, fever, decreased appetite and weight loss. On physical examination, she was noted to have left-sided facial droop, no evidence of any lymphadenopathy of hepatosplenomegaly. Past medical history was significant for fibromyalgia, degenerative joint disease and depression. Further evaluation with a brain CT and brain MRI done at that time did not reveal any abnormality. Complete blood count done at that time was consistent with a white blood cell (WBC) count of 3,530/µL, absolute neutrophil count of 2,850/µL, hemoglobin of 6.1 g/dL, platelet count of 70,000/µL, MCV of 103.9 and LDH of 882 U/L. She also had a temperature of 38.6 °C during her hospital course. It was initially attributed to medications/infection but she developed further worsening of her pancytopenia while in the hospital and hematology was consulted. Further workup showed a normal vitamin B12 and folate level. Infectious workup for CMV, EBV, HIV, hepatitis and human herpes virus-6, influenza, parainfluenza, adenovirus and parvovirus B19 was negative. Extensive rheumatologic workup was also negative. On the iron panel, patient was found to have an elevated ferritin of 40,997 ng/mL with a transferrin saturation of 59%. She also had laboratory evidence of disseminated intravascular coagulation (DIC) as well as a fibrinogen of 80 mg/dL, FDP 20 - 40 µg/mL and INR of 1.8 and hypertriglyceridemia with a level of 491 mg/dL. This raised the suspicion for HLH and a bone marrow biopsy was done which showed hypercellular bone marrow (95% cellularity) with extensive involvement by atypical lymphoid infiltrate composed of pre-
soluble CD25 was within reference range. Patient has symptoms of lymphoma. Repeat ferritin was 1,800 ng/mL and with megaloblastoid erythroid changes with no morphologic bone marrow (50-60%) with trilineage hematopoiesis.

The levels of interferon gamma, soluble interleukin-2 (sIL-2) and interleukin-6 (IL-6) are higher in B-LAHS compared to B-cell lymphoma patients without HLH. This could possibly explain the pathogenesis of B-LAHS, where the lymphoma cells release the inflammatory cytokines that subsequently activate the benign macrophages [9, 13, 14]. The diagnosis of B-LAHS is quite challenging as it can be recognized at the same time as HLH is diagnosed or even earlier. The noticeable differences between T-cell and B-cell LAHS were that B-cell LAHS affected older patients, very rarely involved the bone marrow and caused less DIC [9, 13, 14]. T/NK-LAHS has poor prognosis compared to B-LAHS as it is more aggressive and the median survival for B-LAHS is about 9 months [9, 13, 14].

A recent study showed that the serum soluble sIL-2R/ferritin ratio is a useful marker as it was higher in LAHS compared to other forms of HLH [15]. Serum beta-2 microglobulin levels were found to be significantly higher in HLH patients when compared to healthy individuals. The levels were much higher in LAHS when compared to other forms of HLH. In fact, the overall survival (OS) was dependent on its levels. OS was shorter with levels more than 4.03 mg/L compared to less than 4.03 mg/L. Thus, it was found to be an independent prognostic marker in patients with LAHS.

After the diagnostic studies, the treatment should be initiated promptly in cases with high clinical suspicion, as it is rap-
idly fatal within weeks. The treatment is directed towards the primary etiology - in our case the lymphoma [10-13]. Hence, the treatment of our patient’s DLBCL was started promptly and we saw resolution of her LAHS as her lymphoma responded to chemotherapy. Intrathecal therapy with methotrexate and steroids is used in cases of CNS involvement [11, 12]. Autologous hematopoietic cell transplantation (HCT) is recommended for patients with recurrent HLH, familial HLH, CNS involvement and in cases where there is a progression of the disease despite adequate therapy [11, 12]. At any point if our patient relapses from her disease, our plan is to give her salvage chemotherapy followed by autologous HCT.

It is thus very important to have a high suspicion for HLH, diagnose it promptly and initiate treatment without any delay.

**Conflicts of Interest**

All the authors have no conflicts of interest to disclose.

**References**

1. Chang H, Hung YS, Lin TL, Wang PN, Kuo MC, Tang TC, Wu JH, et al. Primary bone marrow diffuse large B cell lymphoma: a case series and review. Ann Hematol. 2011;90(7):791-796.
2. Hu Y, Chen SL, Huang ZX, Gao W, An N. Case Report Diffuse large B-cell lymphoma in the primary bone marrow. Genet Mol Res. 2015;14(2):6247-6250.
3. Kazama H, Teramura M, Yoshinaga K, Masuda A, Motoji T. Long-term remission of primary bone marrow diffuse large B-cell lymphoma treated with high-dose chemotherapy rescued by in vivo rituximab-purged autologous stem cells. Case Rep Med. 2012;2012:957063.
4. Yamashita T, Ishida M, Moro H, Yamoto H, Uchibayashi S, Yoshii M, Nakanishi R, et al. Primary bone marrow diffuse large B-cell lymphoma accompanying cold agglutinin disease: A case report with review of the literature. Oncol Lett. 2014;7(1):79-81.
5. Devitt K, Cerny J, Switzer B, Ramanathan M, Nath R, Yu H, Woda BA, et al. Hemophagocytic lymphohistiocytosis secondary to T-cell/histiocyte-rich large B-cell lymphoma. Leuk Res Rep. 2014;3(2):42-45.
6. Schram AM, Berliner N. How I treat hemophagocytic lymphohistiocytosis in the adult patient. Blood. 2015;125(19):2908-2914.
7. Oto M, Yoshitsugu K, Uneda S, Nagamine M, Yoshida M. Prognostic Factors and Outcomes of Adult-Onset Hemophagocytic Lymphohistiocytosis: A Retrospective Analysis of 34 Cases. Hematol Rep. 2015;7(2):5841.
8. Henter JI, Horne A, Arico M, Egeler RM, Filipovich AH, Imashuku S, Ladisch S, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124-131.
9. Han AR, Lee HR, Park BB, Hwang IG, Park S, Lee SC, Kim K, et al. Lymphoma-associated hemophagocytic syndrome: clinical features and treatment outcome. Ann Hematol. 2007;86(7):493-498.
10. Bode SF, Lehnberg K, Maul-Pavicic A, Vraetz T, Janka G, Stadt UZ, Ehl S. Recent advances in the diagnosis and treatment of hemophagocytic lymphohistiocytosis. Arthritis Res Ther. 2012;14(3):213.
11. Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041-4052.
12. Javed A, Sheng J, Essex D. Hemophagocytic Lymphohistiocytosis Secondary to Diffuse B-Cell Lymphoma. Journal of Hematology. 2015;4:151-154.
13. Tsuji T, Hirano T, Yamasaki H, Tsuji M, Tsuda H. A high sIL-2R/ferritin ratio is a useful marker for the diagnosis of lymphoma-associated hemophagocytic syndrome. Ann Hematol. 2014;93(5):821-826.
14. Miyahara M, Sano M, Shibata K, Matsuzaki M, Ibaraki K, Shimamoto Y, Tokunaga O. B-cell lymphoma-associated hemophagocytic syndrome: clinicopathological characteristics. Ann Hematol. 2000;79(7):378-388.
15. Jiang T, Ding X, Lu W. The Prognostic Significance of Beta2 Microglobulin in Patients with Hemophagocytic Lymphohistiocytosis. Dis Markers. 2016;2016:1523959.